UPDATE: Feltl Reiterates IDEXX Laboratories Hold, Increases PT to $90

Feltl and Company reiterated its IDEXX Laboratories

Hold rating and increased its price target from $87.50 to $90 in a research report published today. In the report, Feltl and Company stated, "While we believe IDEXX is positioned well for veterinary market recovery, it currently trades near the high end of its historical multiples. We would like to see additional improvement in the veterinary market, an accelerating replacement cycle, or more attractive prices before becoming more positive on the shares." Shares of IDEXX Laboratories were trading at $85.19 at the time of posting, down 1.45% from Friday's market close.